Do you honestly believe that a trial drug that has so far achieved 1 complete response in almost 40 patients is the greater likelihood chance of success in that patient than a modified approved oncology drug that has repeatedly proven to outperform it's parent compound, Herceptin, which already had proven success in multiple cancer types around the world?
Look below...
Enhertu (trastuzumab-deruxtecan) was already approved in Europe early 2023 for Her2-low metastatic breast cancer.
https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html
I read that paper long before you showed me and I was not impressed. It was funded by IMU and this is how they pull you in. I also wouldn't waste my time listening to someone who would fail semester 1 biology.
- Forums
- ASX - By Stock
- Ann: Science Series CHECKvacc
Do you honestly believe that a trial drug that has so far...
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.4¢ |
Change
0.004(5.71%) |
Mkt cap ! $541.6M |
Open | High | Low | Value | Volume |
7.1¢ | 7.4¢ | 7.1¢ | $1.165M | 16.02M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
23 | 682361 | 7.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.4¢ | 346539 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
20 | 661529 | 0.073 |
24 | 819431 | 0.072 |
27 | 3570596 | 0.071 |
71 | 5831041 | 0.070 |
18 | 1524312 | 0.069 |
Price($) | Vol. | No. |
---|---|---|
0.074 | 350670 | 11 |
0.075 | 1873902 | 15 |
0.076 | 700266 | 8 |
0.077 | 489826 | 7 |
0.078 | 1709219 | 12 |
Last trade - 12.37pm 10/05/2024 (20 minute delay) ? |
|
|||||
Last
7.4¢ |
  |
Change
0.004 ( 4.23 %) |
|||
Open | High | Low | Volume | ||
7.1¢ | 7.4¢ | 7.1¢ | 8847593 | ||
Last updated 12.57pm 10/05/2024 ? |
Featured News
IMU (ASX) Chart |